Loading stock data…
TARS
$61.55+1.91 (+3.20%)
Market ClosedLast close Jun 9
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tarsus Pharmaceuticals, Inc. in the Healthcare sector is trading at $61.55 with a market capitalization of $2.5B. Wall Street consensus targets $94.11 (9 analysts), implying a +52.9% move over the next 12 months. The stock is currently 28% below its 52-week high of $85.25, remaining 9.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +52.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$61.55
Potential Downside
0%
Whystock Fair Value$61.55
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$94.11+52.9%
Range$88.00 – $100.00
Fundamentals
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.53B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.53
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-13.83%
Volume
Today's trading volume
615,559
Recent News
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Long Term Gains
How Tarsus Pharmaceuticals stock has been trading Tarsus Pharmaceuticals (TARS) has caught investor attention after a recent stretch of weak trading, with the stock down 2.5% over the past day, 7.6% over the past week, and 17.8% over the past month. See our latest analysis for Tarsus Pharmaceuticals. At a share price of $59.65, Tarsus Pharmaceuticals has seen recent share price momentum fade, with weaker short term returns set against a much stronger backdrop that includes a 1 year total...
Is It Time To Reassess Tarsus Pharmaceuticals (TARS) After Its Recent Share Price Swings?
If you are asking whether Tarsus Pharmaceuticals at around US$61.21 is offering good value or asking too much, the next sections will break down what the current price really implies. The stock has been volatile recently, with the share price down 5.2% over the last week and 15.6% over the last month, despite still sitting 38.5% higher over the past year and showing a very large 3 year return of 269.6%. These moves have kept Tarsus Pharmaceuticals on many investors' watchlists, as the price...
Tarsus Pharmaceuticals Q1 Earnings Call Highlights
Tarsus Pharmaceuticals (NASDAQ:TARS) reported first-quarter 2026 results highlighted by continued commercial momentum for XDEMVY and progress across its development pipeline, including newly initiated and advancing Phase II programs in Lyme disease prevention and ocular rosacea. XDEMVY sales climb